Lockman

Paul Lockman, PhD, BSN

Professor

Contact

Email
Send an Email
Phone
304-293-0944
Address
PO Box 9530
2037D HSC
Morgantown, WV 26506
Curriculum Vitae
Download Curriculum Vitae

Positions

Professor, Benedum Fellow and the Mylan Endowed Chair

Organization:
West Virginia University School of Pharmacy
Classification:
Fellow

Senior Associate Dean for Research and Strategic Initiatives, School of Pharmacy

Organization:
West Virginia University School of Pharmacy
Department:
Office of the Dean
Classification:
Admin

Professor

Organization:
West Virginia University School of Medicine
Classification:
Faculty

Member

Organization:
West Virginia University WVU Cancer Institute
Classification:
Faculty

Professor

Organization:
West Virginia University School of Medicine
Classification:
Faculty

Education

  • PhD, Texas Tech University

Publications

[2018]

  • Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti MV, Nolan RL, Lockman PR.  Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. Accepted 27 Mar 2018. 
  • Mohammad AS, Griffith JI, Adkins CE, Shah N, Sechrest E, Dolan EL, Terrell-Hall TB, Hendriks BS, Lee H, Lockman PR (2018). Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer. Pharm Res. 2018 Jan 9;35 (2):31.
[2017]

[2016]

[2015]

[2014]

Publications Link

Awards

Recent Scientific Awards

Patent. Lockman PR. "Microfluiduc Device" (2018) Provisional Patent. Patent application for Microfluidic Device (WVU Ref. 2018-018) (Our Ref. WVU 3012-PROV)
Invited Talk; USF & FAMU 2018 Nano-Bio Collaborative International Conference (2018)
TTUHSC President’s Young Investigator Research Award (2009)
TTUHSC School of Pharmacy, Distinguished Alumni Award; Excellence in Research (2010)
Invited Talk; Gordon Research Conference: Barriers of the CNS (2010): Drug delivery to metastatic brain tumors. Colby-Sawyer College, New Hampshire.
Invited Talk; Does Chemotherapy Reach Effective Concentrations for the Treatment of Brain Metastases of Breast Cancer? Medical Rounds – London Health Sciences Center. Invited Seminar and Discussion. London  Ontario, Canada
Invited Talk; Breast Cancer Center of Excellence, Invited Panelist and speaker National Breast Cancer Coalition Fund, Annual Advocacy Training Conference, Washington DC.(2009)
Invited Talk; Challenges and Opportunities to Deliver Drugs in Brain Metastases of Breast Cancer, Invited Seminar, MD Anderson Houston TX (2009)
Invited Talk; Workshop on Drug Delivery in Parkinson’s Disease; Circumventing the Blood-brain barrier (2008):Michael J. Fox Foundation and the Kinetics foundation. San Francisco, CA. 
 
Recent Educational Awards
American Association of Colleges of Pharmacy; Innovations in Teaching Award (2007)
Texas Higher Education Coordinating Board Star Award Finalist (2009)
TTUHSC President’s Excellence in Teaching Award (2008)
P3 Teacher of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007, 2008)
P3 Teaching Team of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007)
P1 Teaching Team of the Year; Texas Tech University HSC, SOP (2004)

Additional Info

Teaching: Clinical Toxicology, Anatomy and Pharmacology

 

 

About Paul Lockman

Dr. Lockman earned his B.S. in Nursing from West Texas A&M University, after which he practiced in intensive care, clinical toxicology and emergency medicine, then went on to earn his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center. Dr. Lockman was an Associate Professor and Associate Dean for Outcomes Assessment and Accreditation at Texas Tech University before transitioning to West Virginia University. Currently, Dr. Lockman is the Douglas Glover Endowed Chair of Basic Pharmaceutical Sciences at West Virginia University School of Pharmacy. He also serves as the Associate Director for Translational Research at the Mary Babb Randolph Cancer Center. Dr. Lockman’s primary research focus is on understanding why chemotherapy has limited distribution, and ultimately fails in brain metastases of breast cancer. 
 

Additional Info

Other organizations that Dr. Lockman is affiliated with

https://neuroscience.wvu.edu/

http://www.wvctsi.org/

http://wvucancer.org/research/

Research Program

Breast Cancer

Research Interests

Dr. Lockman earned his B.S. in Nursing from West Texas A&M University, after which he practiced in intensive care, clinical toxicology and emergency medicine, before earning his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center. Dr. Lockman was an Associate Professor and Associate Dean for Outcomes Assessment and Accreditation at Texas Tech University before transitioning to West Virginia University. Currently, Dr. Lockman is the Douglas Glover Endowed Chair of Basic Pharmaceutical Sciences at West Virginia University School of Pharmacy. He also serves as the Associate Director for Translational Research at the Mary Babb Randolph Cancer Center.

Dr. Lockman’s primary research focus is on understanding why chemotherapy has limited distribution, and ultimately fails in brain metastases of breast cancer.

Research Topics

  • Drug distribution across the Blood-brain barrier
  • Brain tumors
  • Parkinson's disease
  • Stroke

Grants and Research

Research Interests
Chemotherapy distribution into brain tumors and metastases
Nanoparticle drug delivery to brain
Effects of nicotine and or smoking on drug distribution
 
Recent and Current Funding
biOasis; Drug Company Contract  “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer; Survival Project”
National Cancer Institute, National Institutes of Health, Bethesda, MD. 1R01CA166067-01A1 “Prevention and Treatment of Brain Micro-metastases of Breast Cancer”
NEKTAR Therapeutics; Drug company contract “Pharmacokinetics and efficacy of NEKTAR-102 in brain metastases of breast cancer”
biOasis; drug company contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer”
Department of Defense, Breast Cancer Research Program. #BC096887. Cationic Chemotherapeutics to Penetrate Both the Blood-Brain Barrier and Brain Metastasis of Breast Cancer Cells via the Choline Transporter.
Department of Defense, Breast Cancer Research Program. # BC050006. Blood-Tumor Barrier Characterization and Nanoparticle Drug Delivery in Brain Metastasis of Breast Cancer.
Microtransponder; Medical Device Grant “Feasibility of microstimulation for targeted BBB disruption.” 
Minority Health Research and Education Grant program. State of Texas Board of Higher Education; Minority Health Research and Education Grant. Innovations in Competency Education: Strengthening the Pipeline.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. U19 MH069059-01. Development of Novel Treatments for Nicotine Addiction.”